Table 4.
Univariate analysis for the association of patient characteristics with 3-month poor functional outcome in patients who received medical therapy
| Characteristics | Total (n = 241) | Left hemisphere | Right hemisphere | ||||
|---|---|---|---|---|---|---|---|
|
|
|
||||||
| mRS 0–2 (n = 70) | mRS 3–6 (n = 66) | P-value | mRS 0–2 (n = 48) | mRS 3–6 (n = 57) | P-value | ||
| Age, years | 65 (55–70) | 62 (53–71) | 65 (54–70) | 0.505 | 64 (53–70) | 66 (60–70) | 0.143 |
| Male, n (%) | 169 (70.1) | 50 (71.4) | 49 (74.2) | 0.712 | 35 (72.9) | 35 (61.4) | 0.213 |
| Hypertension, n (%) | 156 (64.7) | 48 (68.6) | 43 (65.2) | 0.672 | 28 (58.3) | 37 (64.9) | 0.489 |
| Hyperglycemia, n (%) | 74 (30.7) | 26 (37.1) | 18 (27.3) | 0.219 | 15 (31.3) | 15 (26.3) | 0.577 |
| Hyperlipidemia, n (%) | 50 (20.7) | 15 (21.4) | 10 (15.2) | 0.345 | 9 (18.8) | 16 (28.1) | 0.264 |
| Coronary artery disease, n (%) | 41 (17.0) | 14 (20.0) | 11 (16.7) | 0.616 | 7 (14.6) | 9 (15.8) | 0.864 |
| Atrial fibrillation, n (%) | 40 (16.6) | 14 (20.0) | 10 (15.2) | 0.459 | 7 (14.6) | 9 (15.8) | 0.864 |
| Smoke, n (%) | 95 (39.4) | 30 (42.9) | 25 (37.9) | 0.554 | 16 (33.3) | 24 (42.1) | 0.356 |
| Statins, n (%) | 71 (29.5) | 19 (27.1) | 21 (31.8) | 0.550 | 14 (29.2) | 17 (29.8) | 0.941 |
| Aspirin, n (%) | 79 (32.8) | 22 (31.4) | 21 (31.8) | 0.961 | 19 (39.6) | 17 (29.8) | 0.294 |
| Clopidogrel, n (%) | 52 (21.6) | 15 (21.4) | 14 (21.2) | 0.975 | 13 (27.1) | 10 (17.5) | 0.239 |
| Baseline NIHSS | 8 (4–11) | 6 (2–9) | 11 (7–15) | <0.001 | 5 (3–8) | 9 (6–12) | <0.001 |
| Arterial steno-occlusion site, n (%) | 0.073 | 0.244 | |||||
| ICA | 27 (11.2) | 7 (10.0) | 8 (12.1) | 3 (6.3) | 9 (15.8) | ||
| MCA | 173 (71.8) | 55 (78.6) | 41 (62.1) | 36 (75.0) | 41 (71.9) | ||
| ICA/MCA tandem | 41 (17.0) | 8 (11.4) | 17 (25.8) | 9 (18.8) | 7 (12.3) | ||
| ASPECTS score | 6 (5–8) | 7 (6–8) | 6 (4–7) | <0.001 | 7 (5–8) | 5 (3–7) | <0.001 |
| Caudate nucleus, n (%) | 47 (19.5) | 7 (10.0) | 21 (31.8) | 0.002 | 7 (14.6) | 12 (21.1) | 0.391 |
| Lenticular nucleus, n (%) | 98 (40.7) | 22 (31.4) | 27 (40.9) | 0.250 | 20 (41.7) | 29 (50.9) | 0.346 |
| Internal capsule, n (%) | 51 (21.2) | 12 (17.1) | 14 (21.2) | 0.546 | 6 (12.5) | 19 (33.3) | 0.013 |
| Insula, n (%) | 111 (46.1) | 23 (32.9) | 39 (59.1) | 0.002 | 17 (35.4) | 32 (56.1) | 0.034 |
| M1, n (%) | 65 (27.0) | 12 (17.1) | 23 (34.8) | 0.018 | 9 (18.8) | 21 (36.8) | 0.041 |
| M2, n (%) | 98 (40.7) | 19 (27.1) | 35 (53.0) | 0.002 | 15 (31.3) | 29 (50.9) | 0.042 |
| M3, n (%) | 111 (46.1) | 23 (32.9) | 33 (50.0) | 0.042 | 19 (39.6) | 36 (63.2) | 0.016 |
| M4, n (%) | 88 (36.5) | 16 (22.9) | 33 (50.0) | 0.001 | 16 (33.3) | 23 (40.4) | 0.458 |
| M5, n (%) | 170 (70.5) | 40 (57.1) | 54 (81.8) | 0.002 | 30 (62.5) | 46 (80.7) | 0.038 |
| M6, n (%) | 110 (45.6) | 28 (40.0) | 37 (56.1) | 0.061 | 15 (31.3) | 30 (52.6) | 0.027 |
NIHSS: National Institute of Health Stroke Scale; mRS: modified Rankin Scale; ICA: internal carotid artery; MCA: middle cerebral artery; ASPECTS: Alberta Stroke Program Early CT Score. The bold fonts indicate statistical significance (P < 0.05).